Akebia Therapeutics Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
AKBA Nasdaq 2834 https://akebia.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Akebia Therapeutics Inc

Akebia Therapeutics to Present at H.C. Wainwright Global Investment Conference - May 19th, 2022 12:30 pm
Why Are Akebia Therapeutics Shares Falling Today? - May 16th, 2022 6:13 pm
Akebia Therapeutics (AKBA) Reports Q1 Loss, Tops Revenue Estimates - May 9th, 2022 10:25 pm
Akebia Therapeutics Reports First Quarter 2022 Financial Results and Business Update - May 9th, 2022 8:05 pm
Zoetis (ZTS) Tops Q1 Earnings and Revenue Estimates - May 5th, 2022 12:25 pm
Akebia Therapeutics (AKBA) Expected to Beat Earnings Estimates: Should You Buy? - May 2nd, 2022 7:00 pm
Akebia Therapeutics to Report First Quarter Financial Results - May 2nd, 2022 12:30 pm
Following FDA rejection, Akebia lays off 180 workers - Apr 7th, 2022 7:54 pm
See Why Does HC Wainwright Maintain Neutral On Akebia Stock - Apr 7th, 2022 6:38 pm
Akebia Therapeutics Announces Poster Presentations at National Kidney Foundation Spring Clinical Meetings 2022 - Apr 6th, 2022 12:30 pm
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 4th, 2022 8:30 pm
Akebia: Is There Any Value Left After the CRL? Analyst Weighs In - Apr 1st, 2022 5:55 pm
Akebia stock tumbles after FDA rejects anemia drug - Mar 31st, 2022 4:10 pm
FDA Rejects Akebia Therapeutics' Vadadustat For CKD-Associated Anemia - Mar 30th, 2022 7:34 pm
Akebia Therapeutics Receives Complete Response Letter from the FDA for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients - Mar 30th, 2022 5:33 pm
Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates - Mar 1st, 2022 10:35 pm
Akebia Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Business Highlights - Mar 1st, 2022 9:01 pm
7 Speculative Penny Stocks Worth a Roll of the Dice - Feb 25th, 2022 6:35 pm
Akebia Therapeutics Announces Amendment of License Agreement with Vifor Pharma in Preparation for Potential Vadadustat Launch - Feb 22nd, 2022 1:30 pm
Akebia Therapeutics to Report Fourth Quarter and Full-Year 2021 Financial Results and Discuss Recent Business Highlights - Feb 9th, 2022 1:30 pm